

1

2 **Sex differences in requirements for micronutrients across the lifecourse**

3

4 Ann Prentice^{1,2}

5

6 1. Medical Research Council Nutrition and Bone Health Group, Clifford Allbutt Building,
7 University of Cambridge, Hills Road, Cambridge, CB2 0AH

8 2. Medical Research Council Unit The Gambia at the London School of Hygiene and
9 Tropical Medicine, Fajara, PO Box 273, The Gambia

10

11 **Corresponding author:** Professor Ann Prentice, MRC Nutrition and Bone Health Group,
12 Clifford Allbutt Building, University of Cambridge, Hills Road, Cambridge, CB2 0AH

13 Email: ann.prentice@mrc-lmb.cam.ac.uk

14 Telephone: 01223 763381

15

16 **Short title:** Sex differences in micronutrient requirements

17

18 **Key Words:** Calcium, Dietary Reference Values, Micronutrients, Vitamin D

19

1 **Abstract**

2 For many people, ‘micronutrient requirement’ means the amount needed in the diet to ensure
3 adequacy. Dietary reference values (DRV) provide guidance on the daily intake of vitamins
4 and minerals required to ensure the needs of the majority in the population are covered.
5 These are developed on estimates of the quantity of each micronutrient required by the
6 average person, the bioavailability of the micronutrient from a typical diet and the
7 interindividual variability in these amounts. Sex differences are inherent in the requirements
8 for many micronutrients because they are influenced by body size or macronutrient intake.
9 These are reflected in different DRV for males and females for some micronutrients, but not
10 all, either when data from males and females are combined or when there is no evidence of
11 sex differences. Pregnancy and lactation represent times when micronutrient requirements
12 for females may differ from males, and separate DRV are provided. For some micronutrients,
13 no additional requirement is indicated during pregnancy and lactation because of
14 physiological adaptations. To date, little account has been taken of more subtle sex
15 differences in growth and maturation rates, health vulnerabilities and *in utero* and other
16 programming effects. Over the years, the MRC Nutrition and Bone Health Group has
17 contributed data on micronutrient requirements across the lifecourse, particularly for calcium
18 and vitamin D, and shown that supplementation can have unexpected sex-specific
19 consequences that require further investigation. This paper outlines the current issues and the
20 need for future research on sex differences in micronutrient requirements.

21

22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Micronutrient requirements

The term ‘requirement’ has several meanings in nutritional science and these are often used interchangeably, especially when discussing micronutrients. The ‘biological requirement’ refers to the amount of a nutrient required by the body for essential structural and metabolic functions. The ‘dietary requirement’ refers to the amount of the nutrient in a typical diet that supplies sufficient of the nutrient to meet the biological requirement, and, when applied to a population, is the amount of the nutrient in a typical diet that supplies sufficient of the nutrient to meet the needs of the majority of the population for which the guidelines are set. In the United Kingdom (UK) this latter definition is referred to as the ‘Reference Nutrient Intake (RNI)’, in the US/Canada as the ‘Recommended Dietary Allowance (RDA)’ and in the European Union (EU) as the ‘Population Reference Intake (PRI)’. Where there is insufficient evidence to determine a population dietary requirement for any nutrient, a value referred to as a ‘Safe Intake (SI)’ in the UK or as an ‘Adequate Intake (AI)’ in US/Canada and EU is estimated. These values are known generically as ‘Dietary Reference Values (DRV)’ in the UK and EU and as ‘Dietary Reference Intakes’ (DRI) in US/Canada. Most other national authorities developing dietary requirements for their populations use similar terminology, but often with subtle differences. For clarity in this article, the terms RNI and DRV will be used to denote these various population terms except when referring to a specific set of national reference values, and the discussion will be limited to these three sets of DRV guidelines.

Development of Dietary Reference Values

The definition and methods used to derive DRV are described in detail elsewhere in these Proceedings⁽¹⁾. In brief, those for micronutrients are generally based on an estimate of an average biological requirement, an allowance for the bioavailability of the micronutrient from a diet typical of the population, and consideration of the variability of requirement between individuals, in order to derive an RNI that covers the needs of the majority (generally 97.5%) of the population. Most DRV are developed separately for males and females, and for different ages in bands and, for females, by reproductive status.

The current micronutrient DRV for the UK population were first developed using these principles by the Committee on Medical Aspects of Food Policy (COMA) and published in 1991⁽²⁾. Since that time, those for vitamins A, vitamin D, folate, calcium, sodium, iron, selenium and iodine have been reassessed by COMA and its successor, the Scientific

1 Advisory Committee on Nutrition (SACN), to take account of emerging research. However,
2 the new evidence did not lead to any revision of the DRV for these micronutrients, except
3 those for vitamin D, published in 2016⁽³⁾. The Institute of Medicine (IoM) undertook the
4 derivation of micronutrient DRIs for US/Canada, published in a series of volumes from 1997-
5 2001⁽⁴⁻⁷⁾, with revised values for calcium and vitamin D in 2011⁽⁸⁾ and for sodium and
6 potassium in 2019⁽⁹⁾. More recently, and consequently with a much larger evidence-base to
7 call on, the European Food Safety Authority (EFSA) developed DRV for the EU in a rolling
8 series of assessments for all the micronutrients, summarised in a Technical Report in 2017
9 (with an update in 2019 for sodium and chloride)⁽¹⁰⁾.

10

11 Although there are subtle differences between the DRV developed by each of these 3 national
12 authorities, the criteria on which they are based are remarkably similar. **Table 1** provides, as
13 an illustration, the criteria on which the DRV for 11 of the micronutrients were based for
14 adults. These criteria fall into 5 main categories: (1) the amount of the micronutrient required
15 to avoid the risk of deficiency, as defined by clinical signs or an accepted biochemical
16 threshold; (2) the calculated amount of the micronutrient retained or turned over by the body
17 plus any obligatory losses; (3) empirical data from balance or depletion-repletion studies,
18 often based on biomarker assessments; (4) estimations of usual intake of assumed healthy
19 people in the population, sometimes based on biochemical status markers; and (5) the usual
20 intakes of energy or protein, for those micronutrients required for the metabolism of those
21 macronutrients. A sixth category, mooted strongly in the last 20 years, is an amount of the
22 micronutrient that optimises function and health, at intakes above that needed to avoid overt
23 deficiency. To date, however, a criterion of optimal health and disease risk reduction has
24 only rarely been used for DRV development. This is discussed later for calcium and vitamin
25 D.

26

27 *Sex differences in micronutrient requirements and DRV*

28 For the majority of micronutrients, the selected criterion for the biological requirement
29 includes a component that is related to body size (**Table 1**), and because, on average, males
30 and females differ in size, this automatically introduces the likelihood that adult
31 micronutrient requirements differ by sex, and therefore that sex-specific DRV would be
32 provided. However, relatively few of the adult DRV for vitamins and minerals developed by
33 COMA, IoM and EFSA differ between men and women, and for those that do, this is mainly
34 because the DRV were developed on the basis of the requirement expressed per unit body

1 weight, or per intake of energy or protein. In such instances, the DRV for men is higher than
2 for women when expressed on a unit weight per day basis, e.g. thiamin DRV when expressed
3 in mg/d rather than mg/MJ. For a few micronutrients, the DRV for adult women is greater
4 than that for men at certain ages, the most notable example being iron, which is higher in
5 premenopausal women than men to cover losses during menstruation. The specific case of
6 sex differences in requirements for calcium is discussed more fully later.

7
8 Similar considerations apply to children and adolescents. Micronutrient requirements for
9 children and adolescents are generally based on those for adults with adjustments made for
10 body size at each age (**Table 1**). For some micronutrients in the UK, an interpolation is made
11 between the intake of the micronutrient from breastmilk in infancy and adult intake, using
12 reference weight data to make allowance for size at different ages. In other instances, this is
13 achieved by back extrapolation from adult values based on *pro rata* calculations, using
14 median weights from reference data or, for some micronutrients in the US/Canadian
15 guidelines, metabolic weight (weight^{0.75}) and a growth factor derived from the protein
16 requirements for growth e.g.⁽⁴⁾. The differences in body size between boys and girls
17 throughout childhood and adolescence would indicate that there are sex differences in the
18 dietary requirements for most micronutrients. However, as for adults, different DRV for boys
19 and girls are only provided for some micronutrients, and often only for adolescence.

20
21 Pregnancy and lactation are times when sex differences in micronutrient dietary requirements
22 would be anticipated because of the biological requirements for fetal growth and breast-milk
23 production. An increment to the DRV for adolescent girls and premenopausal women is
24 provided for some micronutrients to allow for these additional requirements, thereby adding
25 to the sex differences in DRV. Where increments are provided (**Table 2**), these are based, in
26 pregnancy, on fetal size or maternal tissue expansion and, in lactation, on the micronutrient
27 content of breast-milk plus the breast-milk intake of breast-fed infants. However, for some
28 micronutrients, there is evidence that such increments are not necessary because of
29 physiological adaptive processes in the mother, such as enhanced intestinal absorption and
30 renal conservation, or because the extra requirement is offset by reduction in needs
31 elsewhere. An example of the former is calcium in pregnancy, when the calcium requirement
32 for fetal growth is met by increases in maternal intestinal absorption and mobilisation of
33 skeletal mineral (discussed in more detail later), and, of the latter, is iron in pregnancy, where
34 the extra requirement for fetal growth is offset by cessation of menstruation in the mother.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Requirements for calcium and vitamin D

Functional outcomes and disease risk reduction

As described earlier, there has been much interest in recent years in developing micronutrient DRV based on functional outcomes, intermediate health markers and disease risk reduction, especially where emerging research has suggested that greater amounts of the micronutrient might be required to prevent deficiency. Two interdependent micronutrients that have attracted much attention in this regard are calcium and vitamin D. Both are essential for skeletal growth and health, at all stages of the lifecourse from fetal life to old age.

Classically, the requirements for these micronutrients have been based on their importance for the skeletal system. Calcium is a primary bone-forming mineral and 98%-99% of body content of calcium is in the skeleton. Vitamin D, through its metabolites 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D, is involved in the control of intestinal absorption, renal conservation and skeletal metabolism of calcium and other related minerals. However, 1-2% of calcium is widespread throughout the body, where it has essential cellular functions, and 1,25-dihydroxyvitamin D is important in the control of many genomic and other cellular processes. On this basis, the possibility that low intakes of calcium and/or poor vitamin D status are implicated in a wide range of non-skeletal conditions and chronic diseases has been proposed by many research groups and has been considered by the DRV Committees in recent years (Figure 1). As there are known differences in the prevalence of many of these health outcomes between males and females, this might signal that the requirements for calcium and vitamin may differ by sex. However, to date, the results of trials and other robust studies investigating these possibilities have either not indicated the anticipated health advantages, or, where there are links, these are generally not at calcium intakes or plasma 25(OH)D concentrations (the biomarker of vitamin D status) above those recommended on the basis of skeletal outcomes. As yet, none of the potential health outcomes listed in Figure 1 has been used for DRV development, except muscle weakness/falls for vitamin D e.g.⁽³⁾.

Sex differences in calcium requirements and DRV

Because there is no recognised specific indicator or biomarker of calcium adequacy, bone mineral content (BMC), bone mineral density (BMD), bone health and fracture risk are considered the main health outcomes for this micronutrient, while DRV development is generally based on calcium retention estimated on theoretical grounds from reference data or

1 measured empirically in balance studies. The factorial method is used for children and
2 adolescence, whereby the calcium retention at each age required for skeletal mineral
3 accretion is combined with estimates of calcium absorption from a diet typical of the
4 population (usually around 30% in Western countries) and losses in urine, faeces and sweat
5 to provide an average dietary requirement on which the DRV are derived (**Table 1**). Calcium
6 retention is estimated from reference BMC/BMD and growth data and from calcium balance
7 studies. In theory, therefore, because boys are taller than girls on average at the same age,
8 with bigger skeletons, there is an expectation of sex differences in skeletal calcium accretion
9 and thus in the DRV for children and adolescents. To date, none of the three DRV
10 Committees have recommended different calcium DRV for boys and girls, except by the UK
11 for ages 11-18y (**Table 3**). Averaged data are used at each age. This implies that more boys
12 than girls will exceed the 97.5 percentile on the average distribution of requirements,
13 meaning that the needs of more than 2.5% of the tallest boys might not be met by the RNI
14 (but fewer than 2.5% of girls), while more girls than boys will fall under the 2.5 percentile on
15 the average distribution, resulting in an overestimate of girls and an underestimate of boys
16 with a requirement not met by the Lower Reference Nutrient Intake (a risk indicator in the
17 UK).

18
19 Similar considerations pertain to the calcium requirements for adult men and women, with
20 values based primarily on calcium retention from balance studies. Osteoporotic fracture risk
21 and bone mineral loss increase in later life and are greater among women than men,
22 especially during the menopause. In the past, there was a presumption that this reflects a
23 degree of calcium deficiency and therefore that calcium requirements increase with age and
24 are greater in women. However, in general, the results of randomised trials and other studies
25 have not borne this out e.g.^(11, 12). Associations between BMC/BMD, fracture risk and
26 customary diet within populations are inconsistent, and on a world-wide basis, populations
27 with a lower risk of osteoporotic fracture are ones with lower customary calcium intake⁽¹³⁾.
28 The evidence is further complicated by the fact that calcium is an antiresorptive agent i.e. it
29 reduces the rate of bone resorption during bone remodelling cycles⁽¹³⁾. Increases in calcium
30 intake, generally by using supplements, therefore produce a measurable but small increase in
31 BMC and BMD for a period of time, a phenomenon known as a bone remodelling transient,
32 but do not slow the rate of bone loss⁽¹³⁾. The use of calcium supplementation to reduce bone
33 resorption at times of bone loss can, therefore, be considered more a pharmacological
34 intervention than a correction of dietary deficiency. None of the 3 DRV Committees felt able

1 to use BMC/BMD or fracture risk as criteria for setting DRV for calcium^(2, 8, 14, 15). However,
2 the IoM did include an increment above the young adult value for menopausal women of 200
3 mgCa/d to “err on the side of caution” in recognition of the effects of an increase in calcium
4 intake on BMD at this stage of life, thereby introducing a sex difference in the US/Canadian
5 DRI⁽⁸⁾. They also applied the same increment for both men and women >70 years of age
6 **(Table 3)**.

7
8 Calcium is essential for fetal growth and breast-milk production at amounts within the
9 distribution of maternal calcium intakes⁽¹⁶⁾. This raises the possibility that women of
10 reproductive age have higher dietary calcium requirements during pregnancy and lactation
11 than other adults. However, it has been recognised for many years that women in populations
12 with a low calcium intake can have many cycles of pregnancy and lactation without apparent
13 calcium deficiency or detriment to their long-term bone health^(2, 17). Physiological
14 adaptations including increased intestinal calcium absorption, mobilisation of bone mineral
15 and, in lactation, renal calcium conservation appear to provide sufficient calcium to meet
16 these requirements without requiring greater dietary calcium intake by the mother^(16, 18). This
17 is discussed in more detail below.

18 19 *Sex differences in vitamin D requirements and DRV*

20 Unlike other micronutrients, vitamin D can be synthesised in the skin by the action of
21 ultraviolet light B (UVB) contained in sunlight. A dietary source of vitamin D is required to
22 maintain good vitamin D status when skin UVB exposure is limited or sunlight contains little
23 or no UVB, such as during the winter in temperate countries. In such circumstances, certain
24 population sub-groups are especially vulnerable to limited skin synthesis and poor vitamin D
25 status. The provision of DRV for vitamin D is to achieve vitamin D sufficiency across the
26 population in all groups. The biomarker of vitamin D status is the circulating metabolite
27 25(OH)D, and the concentration of 25(OH)D below which there is an increased risk of
28 rickets and osteomalacia is used as the main criterion for DRV development for vitamin D,
29 combined with judgements about other aspects of musculoskeletal health such as
30 BMC/BMD, muscle strength, falls, fracture risk and calcium absorption. The dietary intake
31 required to achieve the selected 25(OH)D concentration in the absence of UVB skin exposure
32 is then used to develop the DRV, using data from supplementation and dose-ranging studies.
33 In general, these studies show that children, adolescents and older persons require similar
34 dietary intakes of vitamin D over a period of time to achieve specific 25(OH)D

1 concentrations with no indication of any difference by sex. Consequently, in each of the 3
2 sets of DRV, although different threshold values of 25(OH)D concentration may have been
3 selected for DRV development resulting in different recommended intakes of vitamin D, in
4 each set the same values apply to both males and females and at all stages of the lifecourse
5 except infancy. The exception is that IoM added an increment to the DRI for both men and
6 women >70y, an approach “predicated on caution in the face of uncertainties”⁽⁸⁾ relating to
7 vitamin D intake and fracture risk in older adults.

8

9 The same considerations apply to women during pregnancy and lactation, and none of the 3
10 DRV committees considered that increasing the DRV above that of adults is necessary.
11 However, recent studies suggest that there may be benefits of a higher dietary intake of
12 vitamin D by women during pregnancy and lactation than those currently recommended to
13 boost neonatal and infant vitamin D status, and potentially improve maternal and offspring
14 health outcomes⁽¹⁹⁻²¹⁾. This is a topic of current controversy⁽²¹⁾ and is discussed more fully
15 elsewhere in these Proceedings⁽²²⁾.

16

17 *Sex-specific findings in Gambian and UK studies of calcium requirements*

18 The Gambia, West Africa, has a diet typical of many around the world where milk and milk
19 products are rarely consumed or are in short supply⁽¹³⁾. Calcium intakes in the resource-poor
20 rural regions of The Gambia are very low, averaging 3-4 times less than those indicated by
21 the DRV of UK, US/Canada and EFSA⁽²³⁾. The MRC Nutrition and Bone Health Group has
22 conducted detailed studies over many years, to provide evidence of the health benefits for the
23 people of The Gambia of a higher calcium intake^(14, 24-39). This has been through randomised,
24 placebo controlled trials with long-term follow-up and longitudinal cohort studies,
25 complemented by similar investigations using identical methods and technologies in
26 Cambridge, UK. These have generally not demonstrated the anticipated benefits of higher
27 calcium intakes but, instead, have shown some unforeseen, sex-specific effects with potential
28 consequences for health.

29

30 An early trial by this group in lactating Gambian women, who were supplemented for 12
31 months from 2 weeks postpartum with 1000mgCa/d as calcium carbonate or placebo, was
32 designed to determine the effect on maternal BMC/BMD, biochemical markers of bone
33 turnover, breast-milk calcium content and infant growth⁽²⁴⁾. No significant differences were
34 observed between the mothers and infants in the supplemented and placebo groups for these

1 outcomes. There was, however, evidence in both groups of mothers of bone mineral
2 mobilisation in the first months postpartum with restoration later in lactation, in a similar way
3 to lactating women in Cambridge^(24, 25). These findings added to the accumulating evidence
4 at that time that bone mobilisation is a physiological aspect of lactation and that breast-milk
5 calcium content is not responsive to maternal calcium intake⁽²⁶⁻²⁸⁾. These studies formed part
6 of the evidence that an increase in dietary calcium intake is not necessary during lactation⁽¹⁴⁾.
7 DRV for women developed since that time are the same as those for women and men of the
8 same age (**Table 3**).

9
10 A subsequent trial of pregnant women, who were supplemented from 20 weeks of gestation
11 to delivery with 1500 mgCa/d as calcium carbonate or placebo, was designed to determine
12 the effects of the higher calcium intake on maternal blood pressure and offspring size at birth,
13 and on *post-partum* maternal and infant BMC/BMD, breast-milk calcium content, and infant
14 growth⁽²⁹⁻³¹⁾. None of the anticipated benefits were found, as there were no significant
15 differences between the groups in maternal blood pressure, breast-milk calcium content or
16 fetal and infant growth^(29, 31). Unexpectedly, however, those women who had received the
17 calcium supplement in pregnancy exhibited greater bone mobilisation *postpartum* than those
18 in the placebo group⁽³⁰⁾. In a follow-up study of the mothers after approximately 5 years
19 when the women were not pregnant nor breast-feeding, we showed the expected restoration
20 of BMC/BMD in the mothers in the placebo group but not in those who had received the
21 calcium supplement⁽³²⁾. This opens the possibility that, rather than a benefit, the increase in
22 calcium intake during pregnancy may have had a negative effect on the mother's long-term
23 bone health. To investigate this possibility, a further set of measurements after
24 approximately 20 years has recently been completed, currently under analysis, to determine
25 the impact of calcium supplementation in pregnancy on maternal bone health in mid-life.

26
27 Unexpected results have also emerged from follow-up studies of the offspring of these
28 mothers during childhood and adolescence^(33, 34). These have demonstrated significant sex-
29 specific effects of the maternal supplement on pre-pubertal child growth and bone
30 development at age 8-12 years, such that those girls whose mothers had received the calcium
31 supplement in pregnancy were shorter, lighter and with smaller bones with less bone mineral
32 than girls whose mothers had been in the placebo group. The effects in the boys were the
33 converse, with those whose mothers had received the pregnancy calcium supplement tending
34 to be larger with greater bone mineral than boys whose mothers had been in the placebo

1 group⁽³⁴⁾. These effects on growth and bone development were associated with
2 corresponding sex-specific effects of the maternal supplement on offspring plasma insulin
3 like growth factor 1 (IGF1) concentration in mid-childhood⁽³³⁾. This suggested that the
4 calcium carbonate supplement had altered the *in utero* programming of the offspring growth
5 hormone-IGF1 axis differently in boys and girls, an effect which might be expected to result
6 in sex-specific effects on the timing of puberty and on adolescent growth of the offspring.
7 This possibility is being investigated in continuing follow-up studies.

8

9 Such possibilities have also been suggested by the results of supplementation trials and
10 follow-up studies of pre-pubertal children in The Gambia^(35, 36) and of adolescents in
11 Cambridge⁽³⁷⁾. Gambian boys who participated in a supplementation trial at age 8-12 years,
12 using 750 mgCa/d of calcium carbonate or placebo, entered their pubertal height spurt earlier
13 if they had previously received the calcium supplement than boys in the placebo group⁽³⁵⁾. As
14 a result, the boys in the calcium group were taller in mid-adolescence than the placebo group,
15 but they stopped growing earlier and were shorter in young adulthood, with similar effects on
16 the timing of bone development ^(35, 36). No such effects were observed in the girls^(35, 36). In
17 Cambridge, 12-15 months of supplementation with 1000 mgCa/d as calcium carbonate
18 resulted in greater height and skeletal size but no effect on BMC after size-adjustment in 16-
19 18 year old boys compared to placebo, whereas the calcium supplement resulted in greater
20 size-adjusted BMC but not stature in girls^(38, 39). In both Cambridge trials the calcium
21 supplement was associated with an increase in the circulating concentration of IGF1⁽³⁷⁾. The
22 effect of the calcium carbonate supplementation is likely to represent increased bone growth
23 in the boys and a bone remodelling transient in the girls, similar to that described above for
24 perimenopausal women. In both the Gambian and Cambridge studies, the girls may have
25 been at a later stage of skeletal maturation than the boys at the start of the trials, which may
26 account for some of the sex-specific differences seen. This is because there is a discordance
27 between boys and girls in the timing of pubertal changes and in the cessation of linear growth
28 caused by fusion of the epiphyses at the ends of long bones, with girls maturing at earlier
29 ages than boys.

30

31 Studies such as these suggest the possibility that boys and girls may have subtly different
32 calcium requirements, and that these may be influenced by maternal calcium intake during
33 pregnancy, by changes in calcium intake during childhood and adolescence and by the timing
34 of any intervention relative to the various hormonal and skeletal changes that occur between

1 conception and adulthood. These effects may be due to alterations in the trajectories of
2 growth, resulting in changes to the timing of the pubertal growth spurt and potentially
3 affecting adult size and skeletal characteristics.

4

5 DRV are designed to meet the needs of healthy individuals, including pregnant women, when
6 all other nutrient requirements are met, to prevent insufficiency. Calcium supplements are
7 also prescribed medically to treat certain conditions, such as menopausal and age-related
8 osteoporosis, usually as an adjunct to other medications. The World Health Organization
9 (WHO) currently recommends pregnant women in populations with a low calcium intake to
10 take a calcium supplement of 1500 – 2000 mg/d to prevent pre-eclampsia and its
11 complications, based on the results of several randomised controlled trials⁽⁴⁰⁾. To date, there
12 have been no studies to investigate whether this population-based recommendation has long-
13 term consequences for maternal bone health or offspring growth and development similar to
14 the effects seen in the Gambian studies.

15

16

Summary and concluding remarks

17 Sex differences in micronutrient requirements that are reflected in DRV guidelines are mostly
18 to cover differences in body size or macronutrient intakes, although often average values for
19 males and females are given. To date, little account has been taken of more subtle effects on
20 sex differences in growth and maturation rates, health vulnerabilities or *in utero* and other
21 programming effects. Future research may permit more nuanced sex-specific guidelines.
22 These need to consider potential disadvantages and harms as well as benefits of intakes of
23 micronutrients above those currently consumed by apparently healthy people, and to evaluate
24 possible long-term metabolic consequences on body systems not related to the primary
25 outcome of interest. As studies by the MRC Nutrition and Bone Health Group of calcium
26 requirements in The Gambia and Cambridge have suggested, ‘more’ is not necessarily better.
27 For the present, however, with the limited evidence available for most micronutrients, current
28 DRV values provide the best estimate of population dietary requirements, thereby ensuring
29 adequacy for the majority of individuals, and the provision of average DRV for males and
30 females simplifies, and therefore strengthens, public health messages.

31

32 **Acknowledgements**

1 I gratefully acknowledge the contributions of the study participants and of all members and
2 supporting staff, past and present, of the MRC Nutrition and Bone Health Group in
3 Cambridge and the Calcium, Vitamin D and Bone Health Group in The Gambia.

4

5 **Financial support**

6 The Gambian and Cambridge studies described in this paper were supported by Medical
7 Research Council [Programmes U105960371, U123261351, MC-A760-5QX00] and the
8 Department for International Development (DfID) under the MRC/DfID Concordat. Where
9 there was additional funding for individual components of these studies, they are listed in the
10 published papers cited.

11

12 **Conflicts of interest**

13 None

14

15

1
2 **Table 1. Criteria used in developing dietary reference values for 11 micronutrients: adults and children**

	United Kingdom ^a	US/Canada ^b	European Union ^c	Factor ^d
Adults				
Avoidance of risk of deficiency (clinical signs, biomarker threshold)	B ₁₂ , C, D*	riboflavin, B ₁₂ , C, D†	riboflavin, folate, B ₁₂ , D	x
Factorial method: (retention/turnover+obligatory losses)	A, iron, calcium, potassium,	A, iron	A, C, iron	body size
Balance/depletion-repletion studies (using biomarkers, energy intake)	folate, magnesium,	thiamin, folate, calcium† magnesium	thiamin, calcium	body size
Usual intake or biomarker status	riboflavin	potassium‡	magnesium	body size
Intake of energy/protein	thiamin			body size
Optimisation of function/health (other than frank deficiency)			potassium	x
Children				
Interpolation: infant breastmilk intake and adult value (using reference weights)	A, riboflavin, folate, B ₁₂ , C, iron, magnesium	C	C	body size
Extrapolation: adult values (using reference weights or metabolic weight*growth factor)		A, thiamin, riboflavin, folate, B ₁₂ , magnesium	riboflavin, folate, B ₁₂ , potassium	body size
Extrapolation: from adult value (using energy/protein intake)	thiamin		thiamin	body size
Factorial method: (retention/turnover+obligatory losses)	calcium, potassium	iron, calcium†	A, iron, calcium	body size
Usual intake		potassium‡	magnesium	body size
Same value as adults	D*	D†	D	x

1 **Footnote to Table 1**

2 ^a Developed and published by the Committee on the Medical Aspects of Food Policy 1991⁽²⁾, unless otherwise stated

3 ^b Developed and published by the Institute of Medicine in a series 1997-2001⁽⁴⁻⁷⁾, unless otherwise stated

4 ^c Developed and published by the European Food Safety Authority in a series 2013-2017⁽¹⁰⁾

5 ^d Indicates whether body size is an intrinsic factor of the criterion

6 * Published by the Scientific Advisory Committee on Nutrition 2016⁽³⁾

7 † Developed and published by the Institute of Medicine 2011⁽⁸⁾

8 ‡ Developed and published by the National Academies of Sciences, Engineering, and Medicine 2019⁽⁹⁾

9

1 **Table 2. Criteria used in developing dietary reference values for 11 micronutrients: increments for pregnancy and lactation**

2

	United Kingdom ^a	US/Canada ^b	European Union ^c
Pregnancy			
Fetal growth, maternal tissues, pregnancy outcomes	A, riboflavin, folate, C	A, thiamin, riboflavin, folate, B ₁₂ , C, iron, magnesium	A, riboflavin, B ₁₂ , C
Biomarkers in controlled studies			folate
Usual intake		potassium*	
Adaptation or offset (i.e. no increment)	thiamin, B ₁₂ , D†, iron, calcium, magnesium, potassium	calcium‡, D‡	thiamin, D, iron, calcium, magnesium, potassium
Lactation			
Breastmilk concentration + volume	ribooflavin, folate, B ₁₂ , C, calcium, magnesium	A, thiamin, riboflavin, folate, B ₁₂ , C, iron	A, riboflavin, folate, B ₁₂ , C, potassium
Usual intake		potassium*	
Adaptation or offset (i.e. no increment)	thiamin, D†, iron, potassium	D‡, calcium‡, magnesium	thiamin, D, iron, calcium, magnesium

3

4

1 Footnote to Table 2

2 ^a Developed and published by the Committee on the Medical Aspects of Food Policy 1991⁽²⁾, unless otherwise stated

3 ^b Developed and published by the Institute of Medicine in a series 1997-2001⁽⁴⁻⁷⁾, unless otherwise stated

4 ^c Developed and published by the European Food Safety Authority in a series 2013-2017⁽¹⁰⁾

5 * Developed and published by the National Academies of Sciences, Engineering, and Medicine 2019⁽⁹⁾

6 † Published by the Scientific Advisory Committee on Nutrition 2016⁽³⁾

7 ‡ Developed and published by the Institute of Medicine 2011⁽⁸⁾

1 Table 3. Dietary reference values for calcium (mg/d).

United Kingdom ^a			US/Canada ^b			European Union ^c		
Lifestage	Males	Females	Lifestage	Males	Females	Lifestage	Males	Females
Children								
1-3y	350	350	1-3y	700	700	1-3y	450	450
4-6y	450	450	4-8y	1000	1000	4-10y	800	800
7-10y	550	550						
Adolescents								
11-14y	1000	800	9-13y	1300	1300	11-17y	1150	1150
15-18y	1000	800	14-18y	1300	1300	18-24y	1000	1000
Adults								
19-50y	700	700	19-50y	1000	1000	≥25y	950	950
50+y	700	700	51-70y	1000	1200			
			>70y	1200	1200			
Pregnancy and lactation								
Pregnancy		+0	Pregnancy		+0	Pregnancy		+0
Lactation*		+550*	Lactation		+0	Lactation		+0

2

3

1 **Footnote to Table 3**

2 ^a Reference Nutrient Intake, developed and published by the Committee on the Medical Aspects of Food Policy 1991⁽²⁾ and re-evaluated and endorsed in 1998
3 ⁽¹⁴⁾

4 ^b Recommended Dietary Allowance, developed and published by the Institute of Medicine 2011⁽⁸⁾

5 ^c Population Reference Intake, developed and published by the European Food Safety Authority 2015⁽⁴¹⁾

6 * Lactation for 0-4 months and >4 months; indicated in 1998 that the increment “may not be necessary” ⁽¹⁴⁾

1
2

References

- 3 1. Powers HJ (2021) Approaches to setting dietary reference values for micronutrients,
4 and translation into recommendations. *Proc Nutr Soc (This volume)*.
- 5 2. Department of Health (1991) *Dietary Reference Values for Food Energy and Nutrients*
6 *for the United Kingdom. Report of the Panel on Dietary Reference Values of the*
7 *Committee on Medical Aspects of Food Policy*. vol. 41, *Report on Health and Social*
8 *Subjects*. London: Her Majesty's Stationery Office.
- 9 3. Scientific Advisory Committee on Nutrition (2016) *Vitamin D and Health*.
10 <https://www.gov.uk/government/groups/scientific-advisory-committee-in-nutrition>.
- 11 4. Institute of Medicine (1998) *Dietary reference intakes for thiamin, riboflavin, niacin,*
12 *vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline*. Washington,
13 D.C.: National Academy Press.
- 14 5. Institute of Medicine (2000) *Dietary reference intakes for vitamin C, vitamin E,*
15 *selenium, and carotenoids*. Washington D.C.: National Academy Press.
- 16 6. Institute of Medicine (2001) *Dietary reference intakes for vitamin A, vitamin K,*
17 *arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel,*
18 *silicon, vanadium, and zinc*. Washington, D.C.: National Academy Press.
- 19 7. Institute of Medicine (1997) *Dietary reference intakes for calcium, phosphorus,*
20 *magnesium, vitamin D, and fluoride*. Washington, D.C.: National Academy Press.
- 21 8. Institute of Medicine Food and Nutrition Board (2011) *Dietary Reference Intakes for*
22 *Calcium and Vitamin D*. Washington D.C.: The National Academies Press.
- 23 9. National Academies of Sciences Engineering and Medicine (2019) *Dietary reference*
24 *intakes for sodium and potassium*. Washington, D.C.: The National Academies Press.
- 25 10. European Food Standards Authority (2017) *Dietary reference values for nutrients:*
26 *Summary report*. EFSA Supporting Publication. www.efsa.europa.eu/publications.
- 27 11. Kahwati LC, Weber RP, Pan H *et al.* (2018) Evidence Report and Systematic Review
28 for the US Preventive Services Task Force. *JAMA* 319, 1600-1612.
- 29 12. Uusi-Rasi K, Kärkkäinen MU Lamberg-Allardt CJ (2013) Calcium intake in health
30 maintenance. *Food Nutr Res* 57, 21082.
- 31 13. Prentice A (2004) Diet, nutrition and the prevention of osteoporosis. *Publ Hlth Nutr*
32 7, 227-243.
- 33 14. Department of Health (1998) *Nutrition and Bone Health: with particular reference to*
34 *calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on*
35 *the Nutritional Status of the Population of the Committee on Medical Aspects of the*
36 *Food and Nutrition Policy*. vol. 49, *Report on Health and Social Subjects*.
- 37 15. European Food Standards Authority Panel on Dietetic Products Nutrition and
38 Allergies (2016) Scientific opinion on dietary reference values for vitamin D. *EFSA J*
39 14, 4547,4145pp.
- 40 16. Prentice A (2011) Pregnancy and Lactation. In *Pediatric Bone: Biology and Diseases,*
41 *Second Edition* [Glorieux FH, P JM and Juppner H, editors]. Chennai, India:: Elsevier.
- 42 17. Walker ARP, Richardson B Walker F (1972) The influence of numerous pregnancies
43 and lactations on bone dimensions in South African Bantu and Caucasian mothers.
44 *Clin Sci* 42, 189-196.
- 45 18. Olausson H, Goldberg GR, Laskey MA *et al.* (2012) Calcium economy in human
46 pregnancy and lactation. *Nutrition Research Reviews* 25, 40-67.

- 1 19. O'Callaghan KM, Hennessy A, Hull GLJ *et al.* (2016) Estimation of the maternal
2 vitamin D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a
3 concentration sufficient to keep umbilical cord sera ≥ 25 -30 nmol/L: a dose-response,
4 double-blind, randomized placebo-controlled trial in pregnant women at northern
5 latitude. *Am J Clin Nutr* 108, 77-91.
- 6 20. Wagner CL & Hollis BW (2020) Early-life effects of vitamin D: focus on pregnancy and
7 lactation. *Ann Nutr Metab* 76 suppl 2, 16-28.
- 8 21. Kiely ME, Wagner CL DE R (2020) Vitamin D in pregnancy: where we are and where
9 should we go. *J Steroid Biochem Mol Biol* 201, 105669.
- 10 22. Kiely ME (2021) Risk factors and health impacts of vitamin D, iron and iodine
11 deficiencies in pregnancy. *Proc Nutr Soc (This volume)*.
- 12 23. Prentice A (2002) Calcium nutrition in Gambian children and women. In *Nutritional*
13 *rickets in Nigerian children: the way forward*, pp. 59-62 [Thacher TD, editor]: Nestle
14 Nutrition.
- 15 24. Prentice A, Jarjou LMA, Cole TJ *et al.* (1995) Calcium requirements of lactating
16 Gambian mothers: effects of a calcium supplement on breastmilk calcium
17 concentration, maternal bone mineral content, and urinary calcium excretion. *Am J*
18 *Clin Nutr* 62, 58-67.
- 19 25. Laskey MA, Prentice A, Hanratty LA *et al.* (1998) Bone changes after 3 mo of
20 lactation: influence of calcium intake, breast-milk output, and vitamin D-receptor
21 genotype. *Am J Clin Nutr* 67, 685-692.
- 22 26. Prentice A (1997) Calcium supplementation during breast-feeding. *N Eng J Med* 337,
23 558-559.
- 24 27. Laskey A & Prentice A (1999) Bone mineral changes during and after lactation.
25 *Obstet Gynecol* 94, 608-615.
- 26 28. Prentice A, Laskey MA Jarjou LMA (1999) Lactation and bone development:
27 implications for the calcium requirements of infants and lactating mothers. In
28 *Nutrition and Bone Development*, pp. 127-145 [J-P Bonjour and R Tsang, editors].
29 Philadelphia: Vestey/Lippincott- Raven Publishers.
- 30 29. Jarjou LMA, Prentice A, Sawo Y *et al.* (2006) Randomized, placebo-controlled calcium
31 supplementation study of pregnant Gambian women: effects on breast-milk calcium
32 concentrations and infant birth weight, growth and bone mineral accretion in the
33 first year of life. *Am J Clin Nutr* 83, 657-666.
- 34 30. Jarjou LMA, Laskey MA, Sawo Y *et al.* (2010) Effect of calcium supplementation in
35 pregnancy on maternal bone outcomes among women with a low calcium intake.
36 *Am J Clin Nutr* 92, 450-457.
- 37 31. Goldberg GR, Jarjou LMA, Cole TJ *et al.* (2013) Randomized, placebo-controlled,
38 calcium supplementation trial in pregnant Gambian women accustomed to a low
39 calcium intake: effects on maternal blood pressure and infant growth. *Am J Clin Nutr*
40 98, 972-982.
- 41 32. Jarjou LMA, Sawo Y, Goldberg GR *et al.* (2013) Unexpected long-term effects of
42 calcium supplementation in pregnancy on maternal bone outcomes in women with a
43 low calcium intake: a follow-up study. *Am J Clin Nutr* 98, 723-730.
- 44 33. Prentice A, Ward KA, Nigdikar S *et al.* (2019) Pregnancy supplementation of Gambian
45 mothers with calcium carbonate alters mid-childhood IGF1 in a sex-specific manner.
46 *Bone* 120, 314-320.

- 1 34. Ward KA, Jarjou L, Prentice A (2017) Long-term effects of maternal calcium
2 supplementation on childhood growth differ between males and females in a
3 population accustomed to a low calcium intake. *Bone* 103, 31-38.
- 4 35. Prentice A, Dibba B, Sawo Y *et al.* (2012) The effect of pre-pubertal calcium
5 carbonate supplementation on the age of peak height velocity in Gambian
6 adolescents. *Am J Clin Nutr* 96, 1042-1050.
- 7 36. Ward KA, Cole TJ, Laskey MA *et al.* (2014) The effect of prepubertal calcium
8 carbonate supplementation on skeletal development in Gambian boys - a 12 year
9 follow-up study. *J Clin Endocrinol Metab* 99, 3169-3176.
- 10 37. Ginty F, Prentice A, Laidlaw A *et al.* (2004) *Calcium carbonate supplementation is*
11 *associated with higher plasma IGF-1 in 16-18 year old boys and girls*, *Nutritional*
12 *Aspects of Osteoporosis, 2nd Edition*. Lausanne, Switzerland: Elsevier Science (USA).
- 13 38. Stear SJ, Prentice A, Jones SC *et al.* (2003) Effect of a calcium and exercise
14 intervention on the bone mineral status of 16-18-y-old adolescent girls. *Am J Clin*
15 *Nutr* 77, 985-992.
- 16 39. Prentice A, Ginty F, Stear SJ *et al.* (2005) Calcium supplementation increases stature
17 and bone mineral mass of 16-18 year old boys. *J Clin Endocrinol Metab* 90, 3153-
18 3161.
- 19 40. World Health Organization (2018) *WHO recommendation: Calcium supplementation*
20 *during pregnancy for the prevention of pre-eclampsia and its complications*. Geneva:
21 World Health Organization.
- 22 41. European Food Standards Authority Panel on Dietetic Products Nutrition and
23 Allergies (2015) Scientific opinion on dietary reference values for calcium. *EFSA J* 13,
24 82pp.
25

Figure 1.
Non-skeletal health outcomes considered during development of current dietary reference values for calcium and/or vitamin D

<p><i>All ages</i> All cause mortality Immune modulation, asthma, atopic disorders Autoimmune diseases: Diabetes type 1 Inflammatory bowel and Crohn’s disease Multiple sclerosis Rheumatoid arthritis Systemic lupus erythematosus Susceptibility to infection: Tuberculosis Respiratory infections, influenza, COVID-19</p> <p><i>Pregnancy/lactation</i> Pregnancy-induced hypertension Pre-eclampsia/eclampsia Premature birth Birth outcomes Breastmilk composition</p>	<p><i>Fetal life/infancy</i> Poor organ development Lifelong programming: Inflammatory and autoimmune diseases Cognitive and psychological development</p> <p><i>Childhood/adolescence</i> Failure to thrive Muscle weakness, mobility Puberty, breast development</p> <p><i>Older people</i> Muscle weakness, falls Cognitive function, depression, dementia Autism, schizophrenia Cardiovascular diseases, hypertension Diabetes type 2, metabolic syndrome, obesity Age-related macular degeneration Oral health and periodontal disease Cancers</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Footnote to Figure 1.
Non-skeletal health outcomes considered during development of current dietary reference values for calcium and/or vitamin D, compiled from references 3, 8, 14, 15 and 41.